Download Loncar Investments Selects Cancer Research Institute as Exclusive

Loncar Investments Selects Cancer Research Institute as Exclusive
Charitable Partner in Immunotherapy Research Donation Program
Lenexa, Kan., and New York, N.Y. – December 1, 2015 – On Giving Tuesday, Loncar
Investments and the Cancer Research Institute (CRI) announced that they have entered into an
exclusive charitable partnership for the Loncar Cancer Immunotherapy ETF (ticker: CNCR).
Loncar Investments will use royalties it receives as the exchange-traded fund’s index provider to
donate regular contributions to CRI that amount to 4 basis points, or 0.04%, of CNCR’s total
assets.
“Today’s breakthroughs in cancer immunotherapy have emerged from decades of basic scientific
research funded by visionary benefactors, with the Cancer Research Institute at the forefront,” said
Brad Loncar, CEO of Loncar Investments. “As our index supports public companies delivering
these advances to patients, we want to foster that critical early research as well. There is no better
way to do that than to give to an immunotherapy pioneer like CRI.”
“The Cancer Research Institute is pleased to be the recipient of Loncar Investments’ charitable
giving program,” said Jill O’Donnell-Tormey, Ph.D, CEO and Director of Scientific Affairs at
CRI. “Our mission is to fuel the discovery and development of immunotherapies for all forms of
cancer, and we are delighted by how the fund generates awareness of the area.”
Founded in 1953, the Cancer Research Institute is the world’s only non-profit organization
dedicated to harnessing immunotherapy to conquer cancer.
The partnership is a two-year agreement, with an option for renewal in 2017. Loncar Investments
has guaranteed a minimum donation of at least $20,000 per calendar year.
Media Contact:
Lauren Davis for ISE ETF Ventures
[email protected]
610-228-2103
About Cancer Research Institute
The Cancer Research Institute (CRI), established in 1953, is the world’s only nonprofit
organization dedicated exclusively to transforming cancer patient care by advancing scientific
efforts to develop new and effective immune system-based strategies to prevent, diagnose, treat,
and eventually cure all cancers. Guided by a world-renowned Scientific Advisory Council that
includes three Nobel laureates and 27 members of the National Academy of Sciences, CRI has
invested $311 million in support of research conducted by immunologists and tumor
immunologists at the world’s leading medical centers and universities, and has contributed to
many of the key scientific advances that demonstrate the potential for immunotherapy to change
the face of cancer treatment. To learn more, go to www.cancerresearch.org.
About Loncar Investments: Loncar Investments, LLC, the provider of the Loncar
Immunotherapy Index, is committed to making the biotechnology space more approachable to a
wider range of investors. The company is principally owned by biotech investor Brad Loncar.
For more information, follow LoncarFunds on Twitter at @LoncarFunds.
The Funds investment objectives, risks, charges and expenses must be considered carefully before
investing. The summary and statutory prospectuses contain this and other important information
about the investment company, and may be obtained by calling 800.617.0004 or visiting
www.loncarfunds.com. Read it carefully before investing.
Investing involves risk; Principal loss is possible.
The Loncar Cancer Immunotherapy ETF is distributed by Quasar Distributors, LLC.
A basis point is a common unit of measure for interest rates and other percentages in finance. One
basis point is equal to 1/100th of 1%, or 0.01% (0.0001).
The Loncar Cancer Immunotherapy Index is an index of 30 securities that have a strategic focus on
the area of cancer immunotherapy, or harnessing the immune system to fight cancer. Quotes for
the index can be found under the symbol “LCINDX” on the Bloomberg Professional service and
other financial data providers.
One may not directly invest in an index.